Q-omics provides the consensus-scored COPS8 profile across patient tissues and cancer cell-line models. COPS8 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, COPS8 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, COPS8 protein abundance shows 20,417 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, HNSC, and PDAC as cancer lineages where COPS8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COPS8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COPS8 survival associations across molecular data types. COPS8 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COPS8 RNA expression–survival associations across cancer types. High COPS8 expression shows unfavorable associations in UVM, ACC, LIHC, STAD, HNSC and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for COPS8 RNA expression.
This table summarizes COPS8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for COPS8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COPS8 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, LUAD, LIHC and COAD. The HNSC box plot shows higher COPS8 RNA expression in tumor versus normal tissue (log2 FC = +0.799, t-test p < 0.001).
This table shows molecular features associated with COPS8 in patient tissues and cancer cell lines. In patient samples, COPS8 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, COPS8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
